FindTrial
Sign In

18F-FDG-PET

RADIATION4 trials

Sponsors

Hospices Civils de Lyon, Uppsala University, National Cancer Institute (NCI)

Conditions

Aggressive B-cell Lymphoma With Secondary Involvement of the CNSCancer of the Uterine CervixNeuroendocrine TumorsPancreatic Neuroendocrine TumorPrimary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)

Phase 1

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
Active, not recruitingNCT05211336
National Cancer Institute (NCI)Aggressive B-cell Lymphoma With Secondary Involvement of the CNS, Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
Start: 2022-04-19End: 2029-06-01Updated: 2026-01-08

Unknown Phase

Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy
CompletedNCT01663753
Hospices Civils de LyonCancer of the Uterine Cervix
Start: 2012-03-31End: 2018-08-31Updated: 2019-01-07
Biomarker Study in Pancreatic Neuroendocrine Tumours
NCT03130205
Uppsala UniversityNeuroendocrine Tumors
Start: 2017-05-01End: 2022-01-01Target: 30Updated: 2017-08-25
Biomarker Study of Pancreatic Neuroendocrine Tumours
NCT03741517
Uppsala UniversityPancreatic Neuroendocrine Tumor
Start: 2019-01-30End: 2024-12-31Target: 40Updated: 2022-05-18

Related Papers

The impact of re‐characterizing metastatic pancreatic neuroendocrine tumors: A prospective study
Journal of Neuroendocrinology2025-05-054 citations